

BMC Public Health

Bio-behavioural HIV and STI surveillance among Men who have Sex with Men in Europe: the Sialon II protocols --Manuscript Draft--

Manuscript Number:	PUBH-D-15-00881R2
Full Title:	Bio-behavioural HIV and STI surveillance among Men who have Sex with Men in Europe: the Sialon II protocols
Article Type:	Study protocol
Section/Category:	Infectious Disease Epidemiology
Funding Information:	
Abstract:	<p>Background Globally, the HIV epidemic is representing a pressing public health issue in Europe and elsewhere. There is an emerging and progressively urgent need to harmonise HIV and STI behavioural surveillance among MSM across European countries through the adoption of common indicators, as well as the development of trend analysis in order to monitor the HIV-STI epidemic over time. The Sialon II project protocols have been elaborated for the purpose of implementing a large-scale bio-behavioural survey among MSM in Europe in line with a Second Generation Surveillance System (SGSS) approach.</p> <p>Methods/Design Sialon II is a multi-centre biological and behavioural cross-sectional survey carried out across 13 European countries (Belgium, Bulgaria, Germany, Italy, Lithuania, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the UK) in community settings. A total of 4.966 MSM were enrolled in the study (3.661 participants in the TLS survey, 1.305 participants in the RDS survey). Three distinct components are foreseen in the study protocols: first, a preliminary formative research in each participating country. Second, collection of primary data using two sampling methods designed specifically for 'hard-to-reach' populations, namely Time Location Sampling (TLS) and Respondent Driven Sampling (RDS). Third, implementation of a targeted HIV/STI prevention campaign in the broader context of the data collection.</p> <p>Discussion Through the implementation of combined and targeted prevention complemented by meaningful surveillance among MSM, Sialon II represents a unique opportunity to pilot a bio-behavioural survey in community settings in line with the SGSS approach in a large number of EU countries. Data generated through this survey will not only provide a valuable snapshot of the HIV epidemic in MSM but will also offer an important trend analysis of the epidemiology of HIV and other STIs over time across Europe. Therefore, the Sialon II protocol and findings are likely to contribute significantly to increasing the comparability of data in EU countries through the use of common indicators and in contributing to the development of effective public health strategies and policies in areas of high need.</p>
Corresponding Author:	Lorenzo Gios ITALY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	
Corresponding Author's Secondary Institution:	
First Author:	Lorenzo Gios
First Author Secondary Information:	
Order of Authors:	Lorenzo Gios

	Massimo Mirandola
	Igor Toskin
	Ulrich Marcus
	Sandra Dudareva-Vizule
	Nigel Sherriff
	Michele Breveglieri
	Martina Furegato
	Cinta Folch
	Laia Ferrer
	Alexandra Montoliu
	Christiana Nöstlinger
	Wim Vanden Berghe
	Sharon Kühlmann-Berenzon
	Inga Velicko
	Sónia Dias
	Barbara Suligoj
	Vincenza Regine
	Danica Stanekova
	Magdalena Rosińska
	Saulius Caplinskas
	Irena Klavs
	Ivailo Alexiev
	Alexandru Rafila
Order of Authors Secondary Information:	
Response to Reviewers:	Dear Editor, Following your request for clarifications received on 19 Jan 2016 related to the manuscript PUBH-D-15-00881, please find enclosed the amended version of the manuscript where all authors and the related contributions have been amended in the Authors' Contribution section. Sincerely,

Dear Editor,

Following your request for clarifications received on 19 Jan 2016 related to the manuscript PUBH-D-15-00881, please find enclosed the amended version of the manuscript where all authors and the related contributions have been amended in the Authors' Contribution section

Please address all correspondence concerning this manuscript to me at the following address: gios.lorenzo@gmail.com .


Thank you for considering the manuscript for publication.

Sincerely,

Date

Verona, January 22th 2016

Signature

A handwritten signature in black ink, appearing to read 'Lorenzo Gios', written in a cursive style.

--

Lorenzo Gios - lorenzo.gios@ospedaleuniverona.it

CReMPE - Regional Coordination Centre for European Project Management

Veneto Region - Department of Health, C/O The Verona University Hospital

p.le Aristide Stefani 1 - 37126 Verona (VR) – Italy

Tel: +39 045 8121062 – Mob: +39 335 6192552

[Click here to view linked References](#)

Bio-behavioural HIV and STI surveillance among Men who have Sex with Men in Europe: the Sialon II protocols

Lorenzo Gios ^{1§}, Massimo Mirandola ^{1,2}, Igor Toskin ³, Ulrich Marcus ⁴, Sandra Dudareva-Vizule ⁴, Nigel Sherriff ⁵, Michele Breveglieri ¹, Martina Furegato ¹, Cinta Folch ⁶, Laia Ferrer ⁶, Alexandra Montoliu ⁶, Christiana Nöstlinger ⁷, Wim Vanden Berghe ⁷, Sharon Kühlmann-Berenzon ⁸, Inga Velicko ⁸, Sónia Dias ⁹, Barbara Suligoi ¹⁰, Vincenza Regine ¹⁰, Danica Stanekova ¹¹, Magdalena Rosińska ¹², Saulius Caplinskas ¹³, Irena Klavs ¹⁴, Ivailo Alexiev¹⁵, Alexandru Rafila ¹⁶

¹ CReMPE - Regional Coordination Centre for European Project Management

Veneto Region - Department of Health, the Verona University Hospital, Verona, Italy

² Infectious Diseases Section, Department of Pathology, the Verona University

Hospital - Veneto Region, Verona, Italy

³ Department of Reproductive Health & Research, World Health Organization,

Geneva, Switzerland

⁴ Centre for Health Research, University of Brighton, Brighton, UK

⁵ Department for Infectious Diseases Epidemiology, Robert Koch-Institute, Berlin,

Germany

⁶ Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT), Institut

Catala d'Oncologia (ICO), Agencia de Salut Publica de Catalunya (ASPC), Hospital

Universitari Germans Trias i Pujol, Barcelona, Spain

⁷ Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium

⁸ Department of Monitoring and Evaluation, Public Health Agency of Sweden, Solna,

Sweden

⁹ Institute of Hygiene and Tropical Medicine & GHTM, Universidade Nova de

Lisboa, Lisbon, Portugal

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

¹⁰ Centro Operativo AIDS, Dipartimento di Malattie Infettive, Parassitarie ed

Immunomediate, Istituto Superiore di Sanità, Rome, Italy

¹¹ NRC for HIV/AIDS, Slovak Medical University, Bratislava, Slovak Republic

¹² Department of Epidemiology, National Institute of Public Health, National Institute
of Hygiene, Warsaw, Poland

¹³ Centre for Communicable Diseases and AIDS, Vilnius, Lithuania

¹⁴ National Institute of Public Health, Ljubljana, Slovenia

¹⁵ National Reference Laboratory of HIV, National Center of Infectious and Parasitic
Diseases, Sofia, Bulgaria

¹⁶ National Institute of Infectious Diseases Prof. Dr. Matei Bals, Bucharest, Romania

§Corresponding author

Email addresses:

LGI: lorenzo.gios@ospedaleuniverona.it

MMI: massimo.mirandola@regione.veneto.it

ITO: toskini@who.int

UMA: MarcusU@rki.de

SDV: Dudareva-VizuleS@rki.de

NSH: n.s.sherriff@brighton.ac.uk

MBR: michele.breveglieri@ospedaleuniverona.it

MFU: martina.furegato@ospedaleuniverona.it

CFO: cfolch@iconcologia.net

LFE: lfserret@iconcologia.net

AMO: amontoliu@iconcologia.net

1 CNO: cnoestlinger@itg.be

2 WVB: Wvandenbergh@itg.be

3
4 SKB: sharon.kuhlmann-b@folkhalsomyndigheten.se

5
6
7 IVE: inga.velicko@folkhalsomyndigheten.se

8
9 SDI: smfdias@yahoo.com

10
11 BSU: barbara.suligoi@iss.it

12
13 VRE: vincenza.regine@iss.it

14
15
16 DST: danica.stanekova@szu.sk

17
18 MRO: mrosinska@pzh.gov.pl

19
20
21 SCA: saulius.caplinskas@ulac.lt

22
23 IKL: irena.klavs@nijz.si

24
25
26 IAL: ivoalexiev@yahoo.com

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Background

Globally, the HIV epidemic is representing a pressing public health issue in Europe and elsewhere. There is an emerging and progressively urgent need to harmonise HIV and STI behavioural surveillance among MSM across European countries through the adoption of common indicators, as well as the development of trend analysis in order to monitor the HIV-STI epidemic over time. The Sialon II project protocols have been elaborated for the purpose of implementing a large-scale bio-behavioural survey among MSM in Europe in line with a Second Generation Surveillance System (SGSS) approach.

Methods/Design

Sialon II is a multi-centre biological and behavioural cross-sectional survey carried out across 13 European countries (Belgium, Bulgaria, Germany, Italy, Lithuania, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the UK) in community settings. A total of 4.966 MSM were enrolled in the study (3.661 participants in the TLS survey, 1.305 participants in the RDS survey). Three distinct components are foreseen in the study protocols: first, a preliminary formative research in each participating country. Second, collection of primary data using two sampling methods designed specifically for 'hard-to-reach' populations, namely Time Location Sampling (TLS) and Respondent Driven Sampling (RDS). Third, implementation of a targeted HIV/STI prevention campaign in the broader context of the data collection.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Discussion

Through the implementation of combined and targeted prevention complemented by meaningful surveillance among MSM, Sialon II represents a unique opportunity to pilot a bio-behavioural survey in community settings in line with the SGSS approach in a large number of EU countries. Data generated through this survey will not only provide a valuable snapshot of the HIV epidemic in MSM but will also offer an important trend analysis of the epidemiology of HIV and other STIs over time across Europe. Therefore, the Sialon II protocol and findings are likely to contribute significantly to increasing the comparability of data in EU countries through the use of common indicators and in contributing to the development of effective public health strategies and policies in areas of high need.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

KEYWORDS

HIV, surveillance, MSM, Time-Location Sampling, Respondent-Driven Sampling

Background

The HIV epidemic is still representing a pressing public health issue worldwide and in Europe as well (1). Current documents published by the European Centre for Disease Control (ECDC) and focusing on the WHO European Region clarify that 136,235 new HIV diagnoses were reported in 2013, with a rate of 15.7 per 100.000. A total of 1715,434 infections diagnosed in the WHO European Region represent the current number of persons living with HIV.

In terms of transmission, according to the 2013 documents, the highest proportion of new HIV diagnoses was reported in men who have sex with men (MSM): this specific sub-population is accounting for 42% of all new infections in EU/EEA countries (compared to 40.4% in 2012) (2).

For this specific population, in EU/EEA countries where data are available, since 2004 HIV diagnoses have increased by 33%, confirming that MSM could be considered as a very high risk population for acquiring HIV, as a considerable part of the new HIV infected people across Europe is reported among this sub-population.

In addition, in younger MSM an increase of new diagnoses is dramatically reported for the EU/EEA area: between 2004 and 2013, the number of new HIV positive MSM aged 20-24yrs almost doubled, whilst in adult MSM (30-39 years old) the estimates remain relatively stable. These high estimates (for the new diagnoses in particular) could be partially due to increasing HIV testing behaviours, but this could be also related to onward transmission in this specific population. Indeed, with regards the latter, according to the current scientific literature an increase of high risk sexual practices (such as unprotected anal intercourse) has been reported among MSM across Europe (1; 3)

In terms of serum-status awareness, almost one third of those infected in Europe are estimated to be unaware of their seropositive status (1).

1 Data seems to suggest that the current situation is becoming increasingly critical from
2 a public health perspective.
3

4
5
6
7 Set within this context, HIV diagnosis has become a key surveillance activity for
8 monitoring the HIV epidemic especially in ‘hard-to-reach’ populations such as MSM.
9
10 Reliable data, including trends in risk behaviours over time, are of crucial importance
11
12 in order to understand whether and by how much rates are increasing or decreasing
13
14 and which (sub-) populations are affected the most. Consequently, the international
15
16 literature, such as UNAIDS and WHO reports and publications (4), have stressed the
17
18 need for public health to embrace three main approaches in monitoring and
19
20 controlling the epidemic: (i) a structured surveillance system method; (ii) the use of
21
22 common set of indicators adopted across Europe, and; (iii) specific prevention
23
24 campaigns targeting MSM and testing promotion as the cornerstone of the HIV
25
26 response.
27
28
29
30
31
32

33
34 In terms of structured surveillance initiatives and in response to the growing
35
36 awareness of the urgency for a comprehensive and effective response, a number of
37
38 European countries have implemented surveys specifically targeting MSM (5)
39
40 focusing primarily on the monitoring of risk behaviours. However, a Second
41
42 Generation Surveillance System (SGSS) approach (4), whereby both biological (e.g.
43
44 oral fluid) and behavioural data (e.g. from questionnaires) are collected and analysed
45
46 jointly, has only been adopted in a limited number of countries (6). This is
47
48 problematic and limits the value of such targeted initiatives due to, amongst other
49
50 things, a lack of reliability and comparability of data at the European level (7). A
51
52 SGSS approach is defined by the WHO as the “regular, systematic collection, analysis
53
54 and interpretation of information for use in tracking and describing changes in the
55
56
57
58
59
60
61
62
63
64
65

1 HIV/AIDS epidemic over time” (8). SGSS is important because it not only allows the
2 public health sector to monitor the spread of infections in a given population and to
3
4 analyse trends over time, but it can also facilitate countries to improve their planning
5
6 and evaluation of prevention and treatment activities.
7

8
9 With regards to the second approach (i.e. the use of a common set of indicators
10
11 adopted across Europe to monitoring and controlling the epidemic), despite some
12
13 European countries adopting a SGSS approach, implementation is regrettably patchy
14
15 and not systematic. Furthermore, even where examples of a SGSS approach are
16
17 evident, there is often considerable variation between countries in terms of specific
18
19 indicators utilised and reported. Such challenges highlight the need for HIV and STI
20
21 behavioural surveillance among MSM across EU countries to be harmonised for high-
22
23 risk population such as MSM (5). This call to action has been taken up by the United
24
25 Nations General Assembly in 2001, which in a Special Session on HIV/AIDS
26
27 proposed the construction of a set of core indicators, namely the UNGASS indicators
28
29 (9; 10) to kick-start such harmonisation in the collection of data at the international
30
31 level. These UNGASS indicators have been revised and updated periodically until
32
33 post-2012 when they became known as the Global AIDS Response Progress
34
35 Reporting (GARPR) indicators (see (11) for the most recent guidelines, released at the
36
37 beginning of 2014).
38
39

40
41 In terms of the third approach (i.e. targeted prevention campaigns), such specific
42
43 HIV/STI prevention campaigns targeting MSM and promoting testing represent the
44
45 cornerstone of the HIV response. Yet although many EU Member States (public
46
47 health sectors and voluntary/third sectors) have routinely and for some time,
48
49 implemented prevention programmes targeting MSM specifically, current prevention
50
51 and treatment strategies appear to be not sufficient (12) . It has to be acknowledged
52
53
54
55
56
57
58
59
60
61

1 that the evidence-base for primary HIV prevention does not reach the same degree of
2 graded evidence than bio-medical prevention approaches due to the complexity of
3
4 intertwined behavioural and structural factors. This is not surprising given that health
5 promotion and public health interventions are complex, non-linear, and multi-layered
6
7 processes often with no simple measurable outcomes. They are therefore difficult to
8
9 evaluate, resulting in a general lack of evidence for which HIV programmes might be
10
11 the most effective (13).
12
13
14
15
16
17
18

19 To-date, few studies have been able to address simultaneously all three of the
20
21 approaches to tackling the HIV epidemic as advocated by UNAIDS and the WHO.
22
23 However, of those studies that have embraced such an approach, community-based
24
25 surveys targeting MSM that adopt bio-behavioural measures (e.g. oral fluid testing for
26
27 HIV and behavioural questionnaires) have found high levels of HIV prevalence and
28
29 risk behaviours (such as unprotected anal intercourse) as well as critical levels of HIV
30
31 testing uptake considering the high frequency of unprotected anal intercourse with
32
33 different partners (14; 15). Such studies continue to highlight the urgent need for
34
35 large-scale reliable and comparable second generation surveillance data on MSM that
36
37 are paired with meaningful STI/HIV prevention, treatment and care.
38
39
40
41
42

43 Consequently, and in line with the most recent EC communication on combating
44
45 HIV/AIDS in the European Union and neighbouring countries (2009-2013), the
46
47 overall objective of the Sialon II project is to carry out and promote combined and
48
49 targeted HIV/STI prevention for MSM complemented by second generation HIV/STI
50
51 surveillance in collaboration with UNAIDS and WHO. The project is funded by the
52
53 European Commission under the Second Programme of Community Action in the
54
55 Field of Health (2008-2013). The Sialon II project is based on the experience and
56
57
58
59
60
61
62
63
64
65

1 lessons learned from the former Sialon project, funded under the 2003-2008 Public
2 Health Programme (Work Plan 2007) (15).
3

4 In this paper, the Sialon II project protocols are presented which included three parts:
5

6 (i) the formative research phase (including prevention needs assessment) with the
7 objective to identify the specific community-based settings to carry out data collection
8 and to assess local prevention needs; (ii) the use of innovative surveillance
9 methodologies with the objective to access 'hard-to-reach' MSM in community-based
10 settings; (iii) HIV (HIV1/2) and STI (Syphilis and Hepatitis [HBV/HBC]) testing
11 algorithms, the implementation of targeted prevention activities with the objective to
12 respond to immediate prevention needs when conducting the data collection.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Methods

1
2
3
4 The Sialon II project is a multi-centre biological and behavioural cross-sectional
5
6 survey carried out across 13 European countries including: Belgium, Bulgaria,
7
8
9 Germany, Italy, Lithuania, Poland, Portugal, Romania, Slovakia, Slovenia, Spain,
10
11 Sweden, and the UK. The survey has been implemented using the same
12
13 methodologies (protocols, UNGASS/GARPR indicators, epidemiological algorithms)
14
15 and prevention strategies in each of the participating countries. The project builds on
16
17 an experienced, skilled, and cohesive partnership founded through previous
18
19 collaborations across Europe. All partner institutions are public bodies, representing
20
21 either public health institutes or universities in their respective countries with skilled
22
23 and well-equipped laboratories ensuring capable scientific and technical reporting.
24
25

26
27
28 The Sialon II partnership is rooted more broadly in a further network of local
29
30 collaborating partners ranging from universities, teaching hospitals, epidemiological
31
32 centres, gay and/or HIV non-governmental organisations (NGOs) across all
33
34 participating countries. This extended network has been a key resource for the project
35
36 ensuring on the one hand, relevant specialisation in HIV/STI research, and on the
37
38 other, suitability to social, cultural, policy and political contexts in each country as
39
40 well as actively enabling the participation and views of the target group (MSM) to be
41
42 taken into account.
43
44
45

46
47 In what is to follow, the three related yet distinct components (i.e. formative research;
48
49 primary data collection; targeted prevention activities) are described in more details.
50
51
52
53
54
55
56
57
58
59
60
61
62

Formative Research

1 During 2011-12, formative research (FR) was carried out in all 13 participating
2
3 countries. Information was collected via a combination of a dedicated FR
4
5 questionnaire and focused analysis of secondary data from the European MSM
6
7 Internet Survey (EMIS) (16; 17). The FR questionnaires were completed by each
8
9 project partner from the respective study country in partnership with their local
10
11 collaborating partner (e.g. NGO). Each questionnaire explored a number of areas such
12
13 as: the proposed study site; previous experiences with different study methodologies
14
15 and target groups; data on gay-friendly commercial and non-commercial sites; testing
16
17 opportunities, regulations, and treatment guidelines for HIV, STIs, HBV, and HCV;
18
19 contextual factors such as legislation relating to gay issues (e.g. date of homosexuality
20
21 becoming legal, possibility of gay marriage or officially recognised civil partnerships,
22
23 protection from discrimination regarding sexual orientation etc.) and stigmatisation.
24
25 In addition to the contextual information provided by the country partner, EMIS data
26
27 were also used to further characterise the MSM population in each respective study
28
29 area. This allowed for compiling a comprehensive ‘picture’ of each study area which
30
31 described the relevant context, in which the data collection took place, included
32
33 information such as demographic characteristics, proportions of MSM among the
34
35 adult population, as well as data such as the degree of ‘out-ness’ reported by MSM in
36
37 the study area, self-reported internalised homo-negativity, gay-venue attendance, and
38
39 self-reported HIV and STI history.
40
41
42
43
44
45
46
47
48
49
50
51

52 During the FR process, gay-friendly commercial (e.g. cafés, bars, discos, sex-clubs,
53
54 saunas, porn-shops) and gay friendly non-commercial sites (e.g. community centres
55
56 and cruising areas) were described in detail using a number of indicators such as the
57
58 estimated number of MSM attending the venue per day during a week, opening hours,
59
60
61
62
63
64
65

1 special events, logistical aspects for performing sampling, opportunities for sexual
2 contact in the venue, availability of condoms, lubricants and other prevention
3 activities, and so on.
4
5
6
7
8

9 Findings from the FR were presented and discussed during a dedicated study meeting
10 with all network partners present (including collaborating partners such as NGOs). A
11 FR report was compiled and provided to all national study sites in order to better
12 tailor both the planned TLS and RDS surveys, as well as the targeted prevention
13 actions (17).
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Primary data collection

1 Following, and informed by, the FR phase, a TLS survey (3.661 participants) was
2
3
4 planned and implemented during 2013-2014 in nine cities and countries: Belgium
5
6 (Brussels), Bulgaria (Sofia), Germany (Hamburg), Poland (Warsaw), Portugal
7
8 (Lisbon), Slovenia (Ljubljana), Spain (Barcelona), Sweden (Stockholm), and the UK
9
10 (Brighton). In the remaining four partner countries, an RDS survey (1.305
11
12 participants) was planned and implemented in Italy (Verona), Lithuania (Vilnius),
13
14 Romania (Bucharest), and Slovakia (Bratislava). In all cases the following inclusion
15
16 criteria for MSM participation were used: must have had any kind of sex (oral or anal,
17
18 penetrative or not) at least once with another man during the previous 12 months; able
19
20 to provide anonymous informed consent; agree to complete the study questionnaire;
21
22 to provide either an oral fluid sample (for TLS) or blood sample (for RDS).
23
24
25
26
27
28 Exclusion criteria were: being younger than 18 years old, and having already
29
30 participated in the study.
31
32
33
34

35 Prior to biological sample collection in both TLS and RDS study arms, informed
36
37 consent was collected for each participant. A self-administered pen-and-paper
38
39 questionnaire was then administered to all participants to obtain data on: the social
40
41 and cultural context of respondents; behavioural data on sex practices; risk-reduction
42
43 strategies such as not having anal intercourse with non-steady partners, condom use,
44
45 and HIV serostatus disclosure; STI history; self-reported serostatus, and number and
46
47 type of sexual partners. The questionnaire was designed by the Sialon II network in
48
49 line with the GARPR indicators. A preliminary version of the questionnaire was
50
51 piloted in each country with the collaboration of local gay and/or HIV NGOs.
52
53
54
55 Subsequently, a 'final' English version of the questionnaire was translated into each
56
57 of the languages of the participating countries and then back-translated into English
58
59
60
61
62
63
64
65

for quality control. The same questionnaire was used in both surveys (TLS and RDS):
 in the TLS version additional items were included focusing on the venues in the given
 city (for weight calculations), whilst in the RDS survey extra items were used in order
 to assess the network size of the participants.

In both surveys, in line with the project protocol, a unique identification number
 (barcode) was used in order to identify each questionnaire and to link the behavioural
 information with the biological data (e.g. oral fluid). This approach was used in order
 (i) to guarantee the privacy/anonymity of the participants and (ii) to minimise the
 potential for any mistakes in linking the different types of information (bio-
 behavioural in both TLS and RDS survey).

Table 1 – Timeline in the Sialon II study by sampling method and city

Sampling method	City and Country	Starting month	Ending month
Time-Location Sampling (TLS)	Brussels, Belgium	April 2013	July 2013
	Sofia, Bulgaria	July 2013	September 2013
	Hamburg, Germany	April 2013	August 2013
	Warsaw, Poland	May 2013	September 2013
	Lisbon, Portugal	April 2013	August 2013
	Ljubljana, Slovenia	May 2013	October 2013
	Barcelona, Spain	May 2013	June 2013
	Stockholm, Sweden	May 2013	August 2013
	Brighton, UK	April 2013	June 2013
Respondent-Driven Sampling (RDS)	Verona, Italy	June 2013	June 2014
	Vilnius, Lithuania	June 2013	August 2014

	Bratislava, Slovakia	June 2013	August 2014
	Bucharest, Romania	February 2014	November 2014

Table 2 – MSM enrolled in the Sialon II study by sampling method and city

Sampling method	City and Country	Overall sample
Time-Location Sampling (TLS)	Brussels, Belgium	406
	Sofia, Bulgaria	411
	Hamburg, Germany	408
	Warsaw, Poland	408
	Lisbon, Portugal	409
	Ljubljana, Slovenia	416
	Barcelona, Spain	408
	Stockholm, Sweden	377
	Brighton, UK	418
Respondent-Driven Sampling (RDS)	Verona, Italy	400
	Vilnius, Lithuania	322
	Bratislava, Slovakia	400
	Bucharest, Romania	183
TOTAL		4.966

Time-Location Sampling

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

TLS has been used successfully in previous studies and has demonstrated to be an effective and reliable method for gathering both behavioural and biological data in 'hard-to-reach' populations (14; 18; 19; 20; 15). Based on assumption of an HIV prevalence in the study population of at most 15% based on results from the previous Sialon project, a precision of 5%, a significance level of 95% and a design effect of 2, a random clustered sample size of 392 MSM per city was calculated. Taking into account the possibility of invalid samples, a final target of n=408 per city was planned.

With regards to venues and participants eligibility, any physical public or private locations attended by MSM could be included as venues in the universe (e.g. commercial venues such as cafés, discos/clubs, bars, sex shop, sex cinema, saunas, spas etc as well as non-commercial venues such as cruising settings and special events). One exception were venues that specifically serve HIV positive members of the priority population, since including these types of venues would artificially increase representation of HIV positive individuals in the final sample. Virtual meeting places such as websites and smartphone apps were not included.

In order to finalise the sampling frame, once the initial list of venues or initial universe of venues was elaborated based on the findings of the formative research, MSM venues and venue-day-time (VDT) units were identified and two sampling frames constructed (19). The first sampling frame (or venues sampling frame) comprised a list of venues that met the attendance requirements and were willing to participate (eligible venues). The second sampling frame (VDT sampling frame) comprised a list of venue-specific sampling periods of four hours each (VDT). In constructing this second frame, for each venue and for each day of the week, the VDT units were determined according to two key criteria: i) logistical feasibility and safety

1 for data collectors; and ii) VDTs were expected to yield at least 10 eligible MSM.

2
3 Consequently, at this stage some venues identified previously as being potential data
4
5 collection sites were excluded due to various reasons such as low levels of attendance
6
7 of eligible MSM participants, specific attendance patterns, and/or operational barriers
8
9 or lack of permission by the venue owners/manager.
10

11 Where possible, in order to verify characteristics of potentially eligible VDTs, project
12
13 partners and/or their collaborating partners (e.g. NGOs) interviewed the respective
14
15 venue owners. This process also allowed (where necessary) the counting of MSM
16
17 attending the VDT by use of a 'clicker' (Type I Enumeration) (21) assuming that most
18
19 attendees would be eligible. In order to discern venue specific sampling periods,
20
21 standardised enumerations were conducted of the MSM attending venues during
22
23 possible high attendance day-time periods. The result of this process was the creation
24
25 of the final VDT sampling frame. As data collection proceeded, these sampling
26
27 frames were then updated on a monthly basis (e.g. where new venues may have
28
29 opened, others closed, or the VDT proved to be unproductive).
30
31

32 Following completion of the final sampling frame, a three-stage sampling plan to
33
34 select venues, VDTs, and participants was used. Based on the monthly sampling
35
36 frames, a set of venues equal to the number of sampling events planned for the
37
38 upcoming month were randomly selected (stage 1 of randomisation). Selected venues
39
40 were then sorted in ascending order of VDTs beginning with the venue with the least
41
42 number of VDTs (which is less flexible for scheduling on the calendar); one VDT was
43
44 selected from this venue (stage 2 of randomisation). The VDT selected was scheduled
45
46 on the calendar by choosing any available day on which the VDT falls. After this
47
48 sampling event was scheduled, a VDT was selected randomly for the next venue. The
49
50 process was repeated for each venue selected in first stage of randomisation. Stage 1
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 and 2 of randomisation were carried out in two independent steps because if they had
2 combined in only one step, the venues with many VDTs would have been more likely
3 to be selected than those with fewer VDTs.
4

5
6
7 In addition to venues, each country could also select purposefully up to a maximum of
8 three events to schedule into the sampling calendar (infrequent events to attract
9 members of the target population e.g. gay pride), and thus were excluded from the
10 sampling frame. As the sampling calendar was filled, if the selected VDT could not be
11 scheduled because there were no days available in any week of the month in question,
12 a new VDT was selected randomly from the remaining VDTs of that venue. If no
13 VDT from that venue could be scheduled in any week of the month, then another
14 venue was selected randomly from the set of venues not chosen in stage 1, until the
15 sampling-event was filled. If there was no choice, overlapping VDTs were scheduled.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 More VDTs than needed were scheduled as alternatives VDTs. When data collectors
32 did not achieve the sample size in the primary venue they could go to an alternative
33 VDT until they had reached the sample size. Alternatives VDTs were scheduled in
34 different days and/or timetable. They also were chosen randomly to minimise
35 selection bias. If an event was cancelled before their occurrence for some unforeseen
36 reasons it was rescheduled, that means to change VDT in another week of the month,
37 the same local, day and period but in another week (alternates venues were not used to
38 replace cancelled sampling events).
39
40
41
42
43
44
45
46
47
48
49
50

51 Data collection was planned from between two to six months during 2013-2014
52 depending on the country in question. The decision of exactly when to commence was
53 based on negotiations between the project partner and collaborating partner and
54 informed by the findings from the FR. In the final stage three of the randomisation,
55
56
57
58
59
60
61
62
63
64
65

eligible men were sampled at selected venues in accordance with the monthly
calendar with the aim to collect information from eight men.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Respondent-Driven Sampling

1 RDS (22) was used to recruit representative samples of MSM linked to the gay
2
3
4 community in each selected city (Verona, Vilnius, Bucharest, and Bratislava). This
5
6 specific approach has been used in previous studies (23; 24; 25) targeting different
7
8 sub-groups or populations (e.g.: MSM, sexual workers, IDUs) and has been shown to
9
10 be a reliable method for gathering both behavioural and biological data in hidden or
11
12 'hard-to-reach' populations.
13
14

15
16 As with TLS, formative research was conducted prior to data collection in
17
18 collaboration with local gay NGOs in each participating city in order to properly
19
20 identify potential interview sites, incentives (amount and type of incentive), expected
21
22 network size in the selected city, as well as characteristics of the network structures.
23
24 According to the RDS literature, for a sample size of 400 between six to eight seeds
25
26 should be selected. For the present study, five MSM seeds were selected in
27
28 collaboration with the local gay NGO (NGO representatives and/or MSM recruited in
29
30 gay venues were designated as seeds by the project team). A specific training session
31
32 for seeds was organised in each city, where the project aims and methodology were
33
34 explained, including confidentiality and other ethical issues arising.
35
36
37
38
39
40
41

42 Selected seeds were requested to identify and recruit peers from their social network.
43
44 For this purpose, each seed was given three 'recruitment coupons', containing a
45
46 unique identification number (barcode), address of the interview location, as well as
47
48 the names and contacts of the research team. A dedicated software package was
49
50 developed by the research team in order to generate and print the recruitment coupons
51
52 (including the identification barcode). This software was designed specifically for
53
54 generating and managing barcodes to be read using a barcode reader, in order to avoid
55
56 any potential mistake in the process of codes management.
57
58
59
60
61

1 A primary and a secondary incentive were delivered according to the RDS approach
2 (26). In order to receive the secondary incentive (an incentive for each recruited peer),
3
4 each participant was required to recruit a maximum of three eligible peers, and each
5
6 of the recruited peers was required to take part in the survey.
7

8
9 Trained health professionals were involved in the collection of the biological sample
10
11 (serum) in each sites, whilst trained project staff was involved in the collection of the
12
13 behavioural information (questionnaire, additional items on the network size
14
15 information), as well as in the coupons distribution process.
16
17

18
19 The screener (project staff) clarified the project goals and methodology, ensuring that
20
21 each participant met the eligibility requirements. Participants were also provided with
22
23 a short document containing all the information related to the survey. After signing
24
25 the consent form, the self-administered behavioural questionnaire was presented to
26
27 the participant and on completion, pre-test counselling was provided according to
28
29 local standard procedures. A biological sample was then collected by the project team
30
31 following the local procedures. All biological samples were labelled with the
32
33 participant's identification number and sent to the laboratory for analysis.
34
35
36

37
38 Participants were provided with the proper incentive as well as with three numbered
39
40 coupons (with a specific code number). Instructions on how to select members of the
41
42 social network were delivered. Finally, the participant was invited to come back to
43
44 pick-up the results of the tests using a card reporting his unique code. When results
45
46 were given, a post-test counselling was offered according to local and WHO
47
48 standards.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Laboratory testing

In line with the scientific literature (27; 28; 29), the algorithms for laboratory testing were developed taking into account both the international gold-standards for STI testing and the local laboratory procedures in each country, as well as the WHO-STI surveillance guidelines.

TLS study

HIV antibodies were tested in oral fluid samples using a non-invasive collection method. To collect oral fluid sample, saliva collection devices (ORACOL; Malvern Medical Developments, Worcester, UK) were used. After collection, oral fluid samples were kept between 4°C and 8°C and sent to the laboratory for HIV/AIDS in the respective countries no more than 72 hours after collection. Before testing the samples were then processed according to the manufacture's procedure.

HIV-antibody testing on the oral fluid samples was performed according to the manufacturer's instructions of GENSCREEN HIV 1/2 version 2, BIO-RAD. All HIV-reactive samples were re-tested with Vironostika HIV Ag/Ab, Biomerieux and double sample volume of oral fluid compared to serum was used for oral fluid testing (the antigen component of the test was not supposed to react if oral fluid samples are used). In the case of an HIV-reactive result in one or both tests, participants who came back for their test results were encouraged during post-test counselling to be re-tested from blood according to the algorithm for RDS study. As a quality control, for each oral fluid sample, a total IgG antibodies ELISA test Human IgG ELISA Kit 1x96, Quantitative / Immunology Consultants Laboratory was used in order to assess the sample suitability for testing. Before testing, each sample was diluted 1/250 by a recovery buffer. Samples below 3.5 titre (cut-off) were excluded from the study as being invalid.

RDS study

1 Serum samples collected through the RDS method were tested for HIV, HVB, HCV
2
3
4 and Syphilis in each country by EC marked commercial diagnostic kits following
5
6 usual testing guidelines. Serum samples were tested first with an HIV 4th generation
7
8 ELISA test. For newly diagnosed individuals, positive results were confirmed from
9
10 the second sample by a Western Blot. Participants with HIV-positive results were
11
12 counselled and subsequently referred into local care systems for further management
13
14 of their HIV status. HIV-positive samples were shipped to a central laboratory under
15
16 refrigerated conditions for Avidity Index calculation.
17
18

19
20 In terms of STI testing, for HBV infections all samples were tested in each
21
22 participating country following usual testing guidelines for HBsAg, anti-HBcAb total
23
24 and anti-HBsAb testing. According to the tests results and to a detailed interpretation
25
26 of the Hepatitis parameters, a prompt referral of participants to reference centre for
27
28 further management of their status was ensured. For HCV infection all samples were
29
30 tested in each participating country following usual testing guidelines. Screening
31
32 testing was performed with ELISA anti-HCV diagnostic kits and HCV reactive
33
34 samples were confirmed using line/strip immunoassays. Participants with positive
35
36 results were referred into the local care systems for further evaluation of their status.
37
38 Finally, for Syphilis, collected serum samples were tested in each participating
39
40 country using treponemal and non-treponemal tests. Each sample was tested by both
41
42 RPR and TPHA qualitative test to assist in the interpretation of results. In the case of
43
44 reactive results RPR and/or TPHA quantitative tests were performed. Participants
45
46 with reactive results were referred into the local care systems for further evaluating
47
48 the need for treatment.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Prevention activities

1 HIV and STI surveillance for both TLS and RDS have been implemented within the
2
3 broader context of the Sialon II prevention activities. HIV/STI prevention and testing
4
5 promotion activities are theoretically grounded in two theoretical concepts, i.e. the
6
7 Minority Stress Model (30) and the Information-Motivation-Behavioural skills model
8
9 (IMB) (31). While the former is a multilevel model predicting health outcomes among
10
11 minority groups such as MSM has contextual relevance, the latter targets individual,
12
13 cognitive and motivational factors. The development of the prevention activities has
14
15 also been informed by the formative research activities (see above). In order to ensure
16
17 comparability across data collection sites, the Sialon II prevention protocols describe
18
19 the different prevention and training activities for field implementation including: (i)
20
21 prevention packages (comprising condoms, lubricants, and leaflets with specifically
22
23 tailored information) which have been developed, designed, and distributed to the
24
25 target group throughout the data collection period, and (ii) interactive peer-to-peer
26
27 health education activities that took place at the end of the enrolment process (or in
28
29 case the participant declined to be enrolled). These activities focused on improving
30
31 knowledge and building motivation for safer-sex among the participants along the
32
33 theoretical dimensions of the IMB model. On the basis of a series of multiple-choice
34
35 question cards, participants exchanged information on sexual health, HIV/STI
36
37 prevention and testing with data collectors/educators or seeds. In addition (or
38
39 alternatively depending on the situation), HIV/STI prevention information has been
40
41 offered to participants.
42
43
44
45
46
47
48
49
50

51 As a further support mechanism, a dedicated section of the Sialon II project website
52
53 was developed to include HIV/STI prevention information as well as local voluntary
54
55 counselling testing (VCT) services. In each country, project teams consulted local
56
57 NGOs with regards to appropriate ‘MSM friendly’ voluntary counselling testing
58
59
60

1 (VCT) sites both in the respective cities and at regional levels. This inventory
2 informed the final selection of VCT services made available to respondents through
3 the prevention package. Moreover, TLS data collectors/educators and RDS-seeds
4 received a specific training session based on the Sialon II prevention manual which
5 included information on HIV/STI prevention and testing, adaptable strategies for
6 different situations and settings to empower participants to adopt healthy behaviours,
7 and the role of meaningful HIV/STI surveillance and prevalence data in prevention
8 activities (17). For RDS, participants additionally benefited from discussing
9 prevention issues during the pre/post-test counselling sessions at the participating
10 study sites.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **Ethical issues**

28 In order to comply with all ethical and legal obligations, in both TLS and RDS
29 surveys the name of the participant has not been collected. As noted earlier, a unique
30 barcode was attached to the questionnaire and to the biological sample for each
31 individual allowing anonymous linkage between the two kinds of information for later
32 analysis. Finally, the result of the tests was made available to the study participants
33 through the same barcode attached to a card given to individuals during the sample
34 collection.
35
36
37
38
39
40
41
42
43
44

45 Participants enrolled in the study were asked to provide informed consent. Individuals
46 were given the possibility to withdraw from study at any time without explanation. In
47 case of a confirmed positive test, participants were offered a confirmation test on a
48 different biological sample and encouraged referred into local care for further checks
49 and treatment in line both with the international guidelines and local standard
50 pathways of care.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

In order to ensure no harm for the respondents enrolled in the Sialon II surveys and to harmonise all the data collection procedures, a specific training manual for data collectors has been developed. The coordinators were also in charge of monitoring the local data collection and coaching the data collectors during the task. On-going monitoring activities were carried out so that any potential difficulty or issue in preserving privacy and confidentiality was supervised.

The Sialon II protocols have been submitted to the relevant ethics committee in each participating city, where official approval was obtained prior to any data collection.

The ethics committee which granted approval were: Instituut voor Tropische Geneeskunde, Antwerp (Belgium); National Centre of Infectious and Parasitic Diseases, Sofia (Bulgaria); Robert Koch Institute Charite, Berlin (Germany); Azienda Ospedaliera Universitaria Integrata – Verona University Hospital (Italy); Vilniaus Regioninis Biomediciniu Tyrimu Etikos Komitetas Vilnius Medical University (Lithuania); Komisja Bioetyczna Narodowym Instytucie Zdrowia Publicznego, Warsaw (Poland); Conselho de Ética do Instituto de Higiene e Medicina Tropical, Lisbon (Portugal); Institute Matei Bals, Bucharest (Romania); Slovak Medical University, Bratislava (Slovakia); Komisija Republike Slovenije za Medicinsko Etiko, Ljubljana (Slovenia); German Trias i Puyol Hospital, Barcelona (Spain); Regionala etikprovningarnaden i Stockholm (Sweden); Faculty of Health and Social Science Research Ethics and Governance Committee, University of Brighton (UK).

Parallel to this process, the protocols were first submitted to the WHO Research Project Review Panel (RP2) for the technical approval in 2012, whilst in 2013 the Research Ethics Review Committee (WHO ERC) was consulted for a special evaluation of the ethical components. The Sialon II protocols were approved both by RP2 and by WHO-ERC, thus becoming part of a WHO collaborating study in

1 February 2013. As a consequence of this, periodical monitoring reports on the status
2 of the survey implementation have been prepared and submitted to the WHO-ERC
3
4 committee for review and approval.
5
6
7
8
9

10 **Data analysis and main results**

11 Data analysis will be carried out in line with the sampling method adopted in each
12 study site. Data management will be carried out using DataEntry, R (v3.1.0), STATA
13 (STATA Statistical Software Release 13, College Station, TX: StataCorp LP) and
14 SPSS. In line with the sampling approach adopted, estimates will be weighted. For
15 RDS, the software used for the analysis will be RDS Analyst (www.hpmrg.org), a
16 suite of R commands developed by Mark S. Handcock, Ian E. Fellows, Krista J. Gile
17 (2015 RDS Analyst: Software for the Analysis of Respondent-Driven, Sampling Data,
18 Version 0.52). Data will be analysed as part of the protocol in 2015 and results will be
19 available approximately in 2016.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Discussion

1
2 A second generation surveillance approach to monitoring and controlling the HIV
3
4 epidemic is a critical tool for state-of-the art public health. However to-date, adoption
5
6 of the SGSS approach is far from systematic in terms of implementation across EU
7
8 countries. Consequently, reliable, valid and comparable data on undiagnosed HIV
9
10 prevalence related to sexual risk behaviour in ‘hard-to-reach’ populations such as
11
12 MSM are lacking. This deficiency is problematic because it leaves a considerable gap
13
14 in terms of the ability of European Member States to develop and implement targeted
15
16 and evidence-based HIV/STI prevention strategies. In order to maximise the benefits
17
18 of SGSS approaches, European Member States need to harmonise their HIV and STI
19
20 behavioural surveillance systems through the adoption of a common set of indicators
21
22 in comparable SGSS studies targeting high-risk populations (5).
23
24
25
26
27

28 This paper describes the protocols of the Sialon II project, the aim of which has been
29
30 the implementation of a large-scale bio-behavioural survey among MSM in Europe
31
32 using a SGSS approach, as well as the carrying out of meaningful and targeted
33
34 HIV/STI prevention. These project protocols offer an important contribution to the
35
36 epidemiology of HIV/STIs as well as European public health more broadly.
37
38
39

40 Specifically, implementation of the Sialon II protocols, which take into account the
41
42 most recent GARPR indicators (11), offer a unique opportunity to pilot a large-scale
43
44 bio-behavioural survey in line with the SGSS approach in a substantial number of EU
45
46 countries. The Sialon II protocol and findings (that will be available on the project
47
48 website as well as in additional scientific publications approximately in 2016) are
49
50 likely to contribute significantly to increasing the comparability of data in EU
51
52 countries through the use of common indicators and in implementing effective public
53
54 health strategies and policies in areas of high need. In addition to this, data collected
55
56 through the former Sialon project and through the Sialon II survey could represent the
57
58
59
60
61
62

1 basis for implementing additional surveys – in line with the SGSS – in order to
2 develop trend analysis to monitor the HIV-STI epidemic over time.
3

4 Two key discrete yet linked elements of the protocols appear to be particularly
5 valuable for the implementation of the Sialon II surveillance and prevention
6 programme including: (i) the use of TLS and RDS methodologies to access ‘hard-to-
7 reach’ MSM (sub)populations, and (ii) a project philosophy underpinned by principles
8 of community based participation. In terms of the former, as sex between men is often
9 highly stigmatised in many European countries, MSM can be ‘hard-to-reach’ which in
10 turn, can make HIV/STI surveillance as well as prevention programmes and/or
11 interventions particularly challenging to implement and evaluate.
12
13
14
15
16
17
18
19
20
21
22

23 In terms of limitations, the use of two different sampling strategies could represent a
24 limitation for the study, as it has been shown in other studies that through TLS and
25 RDS methods different segments of the total MSM population can be enrolled and
26 this can result in different sample characteristics, and the differences may persist also
27 after applying weighting corrections to the result estimates: this might limit the results
28 from the Sialon II survey. However, in Sialon II protocols, the deployment of TLS
29 and RDS methods have been particularly beneficial, as they represent the most
30 advanced and available approaches for generating statistically representative samples
31 from ‘hidden’ and most-at-risk populations (in this case MSM).
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Finally, the Sialon protocols may provide a useful and feasible model for community-
46 based organisations to conduct decentralised and de-medicalised HIV testing in the
47 future, as such protocols were tested across highly heterogeneous settings. This
48 approach is increasingly seen as an important strategy to increase coverage of HIV
49 testing and to de-stigmatise and normalise HIV testing in the communities, with the
50 aim to contain the HIV epidemic among MSM.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Conclusions

1
2 It is likely that the implementation of the Sialon II protocols will contribute to a better
3
4 understanding of MSM HIV/STI prevention needs as well as the existence of gaps
5
6 with respect to existing HIV/STI prevention provision. Moreover, by involving the
7
8 MSM community in all aspects of the study through both the partnership itself and
9
10 collaborations with local gay NGOs in the participating countries, as well as working
11
12 intersectorally with public health institutions and universities, it is possible to increase
13
14 the capacity of all stakeholders in using innovative sampling methods for collecting
15
16 bio- behavioural data among MSM in future second generation surveys. The data
17
18 collected through implementing the protocols may contribute to estimating HIV/STI
19
20 prevalence and undiagnosed infections in the MSM population, as well as modelling
21
22 of STI epidemic patterns, increasing comparability of data in EU countries and
23
24 implementing effective public health strategies and policies in areas of high need.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Authors' contributions

1
2
3
4 LGI MMI participated in the development of the RDS component, in the conception
5
6 and design of the protocol and in drafting the manuscript.
7

8
9 LGI, MMI and ITO participated in the WHO review and thereby in the
10
11 refinement and adaptation of the protocols.
12

13
14 UMA and SDV participated in the formative research component, in the conception
15
16 and design of the protocol and in drafting the manuscript.
17

18
19 NSH participated in the conception and design of the protocol and in drafting the
20
21 manuscript.
22

23
24 MFU participated in the early stages of development of the protocols and in drafting
25
26 the manuscript.
27

28
29 MBR participated in the data collectors training component and data collection, in the
30
31 early stages of development of the protocols, in the conception and design of the
32
33 protocol and in drafting the manuscript.
34

35
36 CFO and LFE participated in the TLS component, in the conception and design of the
37
38 protocol and in drafting the manuscript.
39

40
41 SKB and AMO participated in TLS statistical analysis component, the conception and
42
43 design of the protocol and in drafting the manuscript.
44

45
46 CNO and WVB participated in the prevention component, in the conception and
47
48 design of the protocol and in drafting the manuscript.
49

50
51 SDI participated in the conception and design of the protocol, in the protocols
52
53 adaptation to the country specific context, in data collectors training and in drafting
54
55 the manuscript.
56

57
58 BSU and MRO participated in Syphilis and other STIs component, in the conception
59
60 and design of the protocol and in drafting the manuscript.
61

1 IVE, VRE, SCA and IKL participated in the conception and design of the protocol, in
2 the protocols adaptation to the country specific context and in drafting the manuscript.
3

4 DST and IAL participated in the laboratory component, in the conception and design
5 of the protocol and in drafting the manuscript.
6
7
8
9

10
11
12 LGI and MMI amended the final manuscript which was reviewed by all other authors.
13
14
15

16 All authors read, amended and approved the final manuscript.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgements

The authors would like to acknowledge the members of both the WHO Research Project Review Panel (RP2) and the Research Ethics Review Committee (WHO ERC) for their relevant inputs in the revision process, improving considerably the final quality of the protocols. Authors would like to thank the Sialon II colleagues from Associated and Collaborating partners for the constant support, commitment and enthusiasm in the project implementation.

Competing interests

The authors declare that they have no competing interests.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

- 1
2 **1. European Centre for Disease Prevention and Control / WHO. *HIV/AIDS***
3
4 *surveillance in Europe 2012*. Stockholm : European Centre for Disease Prevention
5
6 and Control, 2013.
7
8
- 9 **2. European Centre for Disease Prevention and Control / WHO . *HIV/AIDS***
10
11 *surveillance in Europe 2013*. Stockholm : European Centre for Disease Prevention
12
13 and Control, 2013.
14
15
- 16 **3. European Centre for Disease Prevention and Control. *Evidence Brief. Men who***
17
18 *have Sex with Men. Monitoring implementation of the Dublin Declaration on*
19
20 *Partnership to Fight HIV/AIDS in Europe and Central Asia: 2012 progress report*.
21
22 Stockholm : European Centre for Disease Prevention and Control, 2012.
23
24
- 25 **4. (UNAIDS), World Health Organization and Joint United Nations Programme**
26
27 **on HIV/AIDS. *Initiating Second Generation HIV Surveillance Systems: Practical***
28
29 *Guidelines*. Geneva : World Health Organization, 2002.
30
31
- 32 **5. *HIV and STI behavioural surveillance among men who have sex with men in***
33
34 *Europe. Elford J, Jeannin A, Spencer B, Gervasoni JP, van de Laar MJ, Dubois-*
35
36 **Arber F, the HIV and STI Behavioural Surveillance Mapping Group. s.l. : Euro**
37
38 **Surveill, 2009, Vol. 14(47):pii=19414.**
39
40
- 41 **6. *Mapping HIV/STI behavioural surveillance in Europe. al, Dubois-Arber et. s.l. :***
42
43 **BMC Infectious Diseases, 2010, Vol. 10:290.**
44
45
- 46 **7. (UNAIDS), World Health Organization (WHO) and Joint United Nations**
47
48 **Programme on HIV/AIDS. *Guidelines for second generation surveillance*. Geneva :**
49
50 **World Health Organization, 2000.**
51
52
- 53 **8. World Health Organisation (WHO).**
54
55 <http://www.who.int/hiv/topics/surveillance/2ndgen/en/>. [Online]
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

9. **World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS (UNAIDS).** *Monitoring the Declaration of Commitment on HIV/AIDS: guidelines on construction of core indicators: 2010 reporting.* Geneva : Joint United Nations Programme on HIV/AIDS (UNAIDS), 2009.

10. **(UNAIDS), Joint United Nations Programme on HIV/AIDS.** *Monitoring the Declaration of Commitment on HIV/AIDS. Guidelines on construction of core indicators – 2008 Reporting UNGASS.* Geneva : Joint United Nations Programme on HIV/AIDS (UNAIDS) , 2008.

11. —. *Global AIDS response progress reporting 2014: construction of core indicators for monitoring the 2011 UN political declaration on HIV/AIDS.* Geneva : Joint United Nations Programme on HIV/AIDS (UNAIDS), WHO Library Cataloguing-in-Publication Data, 2014. ISBN 978 92 4 150.

12. *Meta-Analysis of Single-Session Behavioral Interventions to Prevent Sexually Transmitted Infections: Implications for Bundling Prevention Packages.* **Lisa A. Eaton, PhD,corresponding author Tania B. Huedo-Medina, PhD, Seth C. Kalichman, PhD, Jennifer A. Pellowski, Michael J. Sagherian, Michelle Warren, Ami R. Popat, and Blair T. Johnson, PhD.** s.l. : Am J Public Health, 2012, Vols. 102(11): e34–e44.

13. *A European Seal of Approval in HIV prevention for ‘gay’ businesses: findings from an HIV prevention pilot project in eight European countries.* **Sherriff, N.S., and Gugglberger, L.** s.l. : Perspectives in Public Health, 2014, Vols. 134(3), 150-159.

14. *HIV prevalence and undiagnosed infection among a community sample of gay men in Scotland.* **Williamson LM, Hart GJ.** s.l. : J Acquir Immune Defic Syndr, 2007, Vols. 45(2):224-30.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
15. *HIV bio-behavioural survey among men who have sex with men in Barcelona, Bratislava, Bucharest, Ljubljana, Prague and Verona, 2008-2009.* **Mirandola M, Mirandola M, Folch Toda C, Krampac I, Nita I, Stanekova D, Stehlikova D, Toskin I, Gios L, Foschia JP, Breveglieri M, Furegato M, Castellani E, Bonavina MG, the SIALON network.** s.l. : Euro Surveill, 2009, Vol. 14(48):pii=19427.
 16. **The EMIS Network.** *EMIS 2010. The European Men-Who-Have-Sex-With-Men Internet Survey. Findings from 38 countries.* Stockholm : European Centre for Disease Prevention and Control, 2013.
 17. **The Sialon II Network.** *Prevention Manual and Training. Formative Research Report. Prevention Training Manual. Deliverable of the SIALON II project (D7).* 2012.
 18. *Time-space sampling in minority communities: results with young Latino men who have sex with men.* **Stueve A, O'Donnell LN, Duran R, San Doval A, Blome J.** s.l. : Am J Public Health, 2001, Vols. 91(6): 922-6.
 19. *Surveillance of HIV risk and prevention behaviors of men who have sex with men: a national application of venue-based, time-space sampling.* **MacKellar DA, Gallagher KM, Finlayson T, Sanchez T, Lansky A, Sullivan PS.** s.l. : Public Health Rep, 2007, Vol. 122 Suppl. 1: 39.
 20. *A venue based method for sampling hard-to-reach populations.* **Muhib FB, Lin LS, Stueve A, Miller RL, Ford WL, Johnson WD.** s.l. : Public Health Rep, 2001, Vols. 116 Suppl. 1: 216-22.
 21. **Centers for Disease Control and Prevention.** *National Surveillance of HIV risk and prevention behaviors of men who have sex with men. Protocol guidelines. Behavioural and clinical surveillance branch division of HIV/Aids prevention-*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

surveillance and epidemiology. Atlanta : Centers for Disease Control and Prevention, 2003.

22. *Respondent-Driven Sampling: A New Approach to the Study of Hidden Populations*. **Heckathorn, Douglas D.** s.l. : Social Problems, 1997.

23. *Implementation and Analysis of Respondent Driven Sampling: Lessons Learned from the Field*. **Abu S. Abdul-Quader, Douglas D. Heckathorn, Keith**

Sabin, and Tobi Saidel. s.l. : J Urban Health, 2006, Vols. 83(Suppl 1): 1–5.

24. *Assessment of Respondent Driven Sampling for Recruiting Female Sex Workers in Two Vietnamese Cities: Reaching the Unseen Sex Worker*. **Lisa Grazina Johnston,**

Keith Sabin, Mai Thu Hien, Pham Thi Huong. s.l. : J Urban Health, 2006, Vols. 83(Suppl 1): 16–28.

25. *Simultaneous Recruitment of Drug Users and Men Who Have Sex with Men in the United States and Russia Using Respondent-Driven Sampling: Sampling Methods and Implications*. **Martin Y. Iguchi, Allison J. Ober, Sandra H. Berry, Terry Fain,**

Douglas D. Heckathorn, Pamina M. Gorbach, Robert Heimer, Andrei Kozlov,

Lawrence J. Ouellet, Steven Shoptaw, William A. Zule. s.l. : J Urban Health, 2006, Vols. 86(Suppl 1): 5–31.

26. *Ethical considerations in surveys employing Respondent-Driven Sampling*.

Salaam Semaan, Douglas D. Heckathorn, Don C. Des Jarlais, Richard S.

Garfein. s.l. : Am J Public Health, 2010, Vols. 100(4): 582–583.

27. **(WHO), World Health Organization.** *WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children*. Geneva : WHO Library Cataloguing-in-Publication Data, 2007. ISBN 978 92 4 159562 9.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

28. —. *Guidelines for Using HIV Testing Technologies in Surveillance: Selection, Evaluation, and Implementation*. Geneva : World Health Organization (WHO), 2009.

29. *Which algorithm should be used to screen for Syphilis?* **MJ, Binnicker.** s.l. : CurrOpin Infect Dis, 2012, Vols. 25(1):79-85.

30. *Minority stress and mental health in gay men.* **Mar, Meyer IH.** s.l. : J Health Soc Behav, 1995, Vols. 36(1):38-56.

31. **WA, Fisher JD and Fisher.** *Theoretical approaches to individual-level change in HIV risk behaviour. Handbook of HIV Prevention.* New York : Springer, 2000.

Tables

Table 1 – Timeline in the Sialon II study by sampling method and city

Sampling method	City and Country	Starting month	Ending month
Time-Location Sampling (TLS)	Brussels, Belgium	April 2013	July 2013
	Sofia, Bulgaria	July 2013	September 2013
	Hamburg, Germany	April 2013	August 2013
	Warsaw, Poland	May 2013	September 2013
	Lisbon, Portugal	April 2013	August 2013
	Ljubljana, Slovenia	May 2013	October 2013
	Barcelona, Spain	May 2013	June 2013
	Stockholm, Sweden	May 2013	August 2013
	Brighton, UK	April 2013	June 2013
Respondent-Driven Sampling (RDS)	Verona, Italy	June 2013	June 2014
	Vilnius, Lithuania	June 2013	August 2014
	Bratislava, Slovakia	June 2013	August 2014
	Bucharest, Romania	February 2014	November 2014

Table 2 – MSM enrolled in the Sialon II study by sampling method and city

Sampling method	City and Country	Overall sample
Time-Location Sampling (TLS)	Brussels, Belgium	406
	Sofia, Bulgaria	411
	Hamburg, Germany	408
	Warsaw, Poland	408
	Lisbon, Portugal	409
	Ljubljana, Slovenia	416
	Barcelona, Spain	408
	Stockholm, Sweden	377
	Brighton, UK	418
	Respondent-Driven Sampling (RDS)	Verona, Italy
Vilnius, Lithuania		322
Bratislava, Slovakia		400
Bucharest, Romania		183
TOTAL		4.966